Trial
NCT04049097
Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
ZevraDenmark
Collaborators
University of Kansas Medical Center; University College, London
Condition
Inclusion Body Myositis
Intervention
Arimoclomol
Why stopped
As a consequence of the results of IBM4809 which did not meet any of its efficacy endpoints. The planned duration of open-label treatment was 40 months. After termination, the actual mean duration of treatment was approx. 28 weeks.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-15